Clinical Trials
Dive into the world of clinical trials, where medical innovations are put to the test. Discover ongoing trials, their methodologies, and results. Stay informed about the latest breakthroughs and promising treatments in development. Understand the rigorous process of bringing new therapies to market.
Janssen rejoices at JNJ-2113A’s successful psoriasis study findings
Source – Johnson & Johnson On July 4, 2023, Janssen, a subsidiary of Johnson & Johnson announced positive initial results ...
DATOPOTAMAB DERUXTECAN MEETS DUAL PRIMARY ENDPOINT IN TROPION-LUNG01 PHASE III TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
On July 3, 2023, AstraZeneca presented encouraging top-line results from the TROPION-Lung01 Phase III trial that demonstrated the positive efficacy ...
SELINEXOR AND RUXOLITINIB’S PHASE III TRIAL IN JAKI-NAIVE MYELOFIBROSIS BEGINS
Source – Karyopharm Therapeutics Karyopharm Therapeutics has initiated a Phase III clinical trial (NCT04562389) to evaluate the effectiveness and safety ...
Fezolinetant’s Phase IIIb Trial Demonstrates Promising Topline Results in Treating Menopause-related Vasomotor Symptoms (VMS)
Source – Astellas Pharma Astellas Pharma recently announced positive preliminary findings on June 27, 2023, from the Phase IIIb DAYLIGHT ...
Novel BRG1/BRM Inhibitor in Metastatic Uveal Melanoma Shows Safety and Preliminary Efficacy
Source – Foghorn Therapeutics Foghorn Therapeutics has highlighted the safety and tolerability of FHD-286 in metastatic uveal melanoma (mUM) through ...
Briqulimab Phase I Study Doses First Patient With Lower-Risk MDS
Source – Jasper Therapeutics Jasper Therapeutics has initiated a Phase I trial (NCT05903274) to evaluate the use of briquilimab as ...
Clinical Activity Is Provoked by Teclistamab Triplet in R/R Multiple Myeloma
The Phase Ib (NCT04722146) MajesTEC-2 trial demonstrated promising clinical activity in patients with relapsed/refractory multiple myeloma (RRMM) when combining teclistamab ...
Missed trial procedures, made-up emails, and an unsuccessful endpoint make a mess Alzheimer’s agitation readout from BioXCel
Source – BioXcel Therapeutics On June 29, 2023, a potential breakthrough in the treatment of agitation episodes in Alzheimer’s disease ...
Imfinzi + Imjudo: Unprecedented 4-Year Survival in Advanced Liver Cancer
Source – AstraZeneca On 29 June 2023, new findings from the HIMALAYA Phase III trial revealed that AstraZeneca’s Imfinzi (durvalumab) ...
Combining mitazalimab with chemotherapy demonstrates significant antitumor activity in metastatic pancreatic ductal adenocarcinoma
Source – Alligator Bioscience On June 26, 2023 the combination of mitazalimab, a novel CD40 monoclonal antibody agonist, with chemotherapy ...
Epcoritamab Shows Promise in Follicular Lymphoma Trial
Source – Abbvie On 28 June 2023, AbbVie in collaboration with Genmab, disclosede the initial findings of the Phase I/II ...
Promising Objective Response Rate (ORR) Observed in Phase II Trial of Envafolimab for Sarcoma
Source: TRACON Pharmaceuticals Positive findings from the ongoing Phase II ENVASARC trial (NCT04480502) demonstrate that envafolimab (KN035), either as a ...
Lilly’s Retatrutide Shows Promising Phase II Results By Weight Reduction in Adults with Obesity and Overweight
Source – Eli Lilly On June 26, 2023, Eli Lilly and Company announced the release of new Phase II findings ...
Promising Phase IIb Results in Atopic Dermatitis: amlitelimab as a Groundbreaking Treatment
Source – Sanofi On June 27, 2023, Sanofi announced positive Phase IIb Results. Amlitelimab shows promise as a first-in-class investigational ...
Pfizer Shares Progress of Clinical Development Program for GLP-1-RA in Adults with Obesity and Type II Diabetes Mellitus
Source – Pfizer On June 26, 2023, Pfizer Provides Update on Clinical Development Program for GLP-1-RA in Obesity and Type ...
Altuviiio a weekly Administration Provides Effective Bleed Prevention for Severe Hemophilia A in Children
Source – Sanofi On June 26, 2023, at the Annual Meeting of the International Society on Thrombosis and Haemostasis (ISTH) ...
Lilly’s SURMOUNT-2 Study Shows Tirzepatide Achieves Significant 15.7% Weight Reduction in Adults with Obesity and Type 2 Diabetes
Source – Eli Lilly On June 24, 2023, Eli Lilly and Company’s tirzepatide showed promising results in the SURMOUNT-2 Phase ...
Positive Phase IIIa Results: Once-Weekly Insulin Icodec Benefits Adults with Type 2 Diabetes
Source – Novo Nordisk Novo Nordisk, on June 25, 2023, released new findings from Phase IIIa trials, ONWARDS 1 and ...
Lilly’s Orforglipron Shows Promising Weight Reduction in Obesity and Overweight Patients: Phase II Findings
Source – Eli Lilly On June 23, 2023, Eli Lilly and Company announced the Phase II results for orforglipron, an ...
Bayer Initiates Phase III Trial of Finerenone in Adults with Type 1 Diabetes and Chronic Kidney Disease
Source – Bayer On June 22, 2023, Bayer Initiates Phase III Trial of Finerenone, Bayer announced the initiation of a ...
Advanced Classical Hodgkin Lymphoma: BrECADD Shows Noninferiority to eBEACOPP
Source – BrECADD According to information from the Phase III HD21 trial (NCT02661503), which included patients with advanced classical Hodgkin ...
In R/R TRBC1+ Patients, AUTO4 CAR T-Cell Therapy Is Well Tolerated Lymphoma T-cell in the periphery
Findings from the first-in-human AUTO4-TL1 trial (NCT03590574), which were presented at the 17th Annual International Conference on Malignant Lymphoma, showed ...
In patients with treatment-naive CLL, Venetoclax Plus Obinutuzumab Shows Durable Survival Benefits
According to 6-year results from the Phase III CLL14 trial (NCT02242942), fixed-duration venetoclax (Venclexta) plus obinutuzumab (Gazyva) therapy resulted in ...
Merck’s Keytruda fails a study for early stomach cancer following metastatic disease victory
Source – Merck Inhibiting immune checkpoints hasn’t been very effective against stomach cancer. Merck has now added another failure to ...
Takeda Unveils Complete Phase III Trial Results for HYQVIA as Maintenance Therapy in CIDP at PNS Annual Meeting
Source: Takeda Takeda on June 20, 2023, released the complete findings from the pivotal Phase III ADVANCE-CIDP 1 clinical trial, ...
Keytruda Triumphs: Promising Progression-Free Survival in HER2-Positive Gastric Cancer
Source: Merck Merck’s renowned cancer drug, Keytruda, may soon see an updated label for its effectiveness in treating HER2-positive stomach ...
Groundbreaking Clinical Trial Confirms Effectiveness of Emgality in Preventing Episodic Migraines
Source: Eli Lilly and Company On June 16, 2023, Eli Lilly and Company released the findings of the CHALLENGE-MIG clinical ...
Skyrizi from AbbVie wins a maintenance trial for ulcerative colitis and is poised to receive FDA approval
Source – Abbvie On 16 June 2023, Risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint ...
98% ORR in Early-Stage Classical Hodgkin Lymphoma with Brentuximab Vedotin + Nivolumab/Chemo
Source – Seagen Frontline treatment with the combination of brentuximab vedotin (Adcetris), nivolumab (Opdivo), doxorubicin, and dacarbazine led to an ...
Clinical Activity is Induced by Ziftomenib in NPM1-mutant R/R AML
Source – Kura Oncology Phase I data from the KOMET-001 trial (NCT04067336) showed that treatment with Ziftomenib, a menin-MLL (KMT2A) ...
